News
BIVI
0.4926
+0.76%
0.0037
BioVie Presents Data Showing Potential For Bezisterim To Reduce Inflammation And Restore Homeostasis In A Manner Correlated With Alzheimer's Disease And Biomarker Endpoints
New data shows how bezisterim may be restoring homeostasis via specific genes associated with dementia, metabolism, and inflammation. Data presented at 12th Annual Alzheimer's & Parkinson's Drug Development Summit in Boston. Data based on analysis of data from BioVie's Phase 3 trial in Alzheimer's disease. Patients treated with bezistersim experienced an age deceleration advantage on four biological clocks.
Benzinga · 1d ago
12 Health Care Stocks Moving In Wednesday's Pre-Market Session
Immutep (NASDAQ:IMMP) stock increased by 15.5% to $2.9 during Wednesday's pre-market session. Syra Health stock rose 14.96% during the session. Sage Therapeutics and Evotec were among the losers in the day's trading.
Benzinga · 2d ago
Weekly Report: what happened at BIVI last week (0415-0419)?
Weekly Report · 4d ago
BIOVIE INC - ON APRIL 18, RECEIVED NOTICE OF DELISTING OR FAILURE TO SATISFY CONTINUED LISTING RULE OR STANDARD FROM NASDAQ
Reuters · 6d ago
BioVie To Present Data Showing How NE3107 Potentially Restores Homeostasis Via Specific Genes Associated With Dementia, Metabolism, And Inflammation
BioVie's "bezisterim" approved as the non-proprietary name for NE3107, an orally active product candidate being studied in Parkinson's Disease and Alzheimer's Disease. Oral presentation and poster presentation will be shared at the 12th Annual Alzheimer's & Parkinson's Drug Development Summit in Boston.
Benzinga · 04/18 12:09
12 Health Care Stocks Moving In Monday's After-Market Session
Dynatronics (NASDAQ:DYNT) stock increased by 70.1% to $0.63 during Monday's after-market session. Cardio Diagnostics Hldgs stock rose 14.28% and Aptorum Gr shares rose 12.61%. Poseida Therapeutics ( NASDAQ:PSTX) shares declined by 15.2% during the session.
Benzinga · 04/15 20:31
Weekly Report: what happened at BIVI last week (0408-0412)?
Weekly Report · 04/15 09:35
Weekly Report: what happened at BIVI last week (0401-0405)?
Weekly Report · 04/08 09:37
12 Health Care Stocks Moving In Monday's After-Market Session
OpGen (NASDAQ:OPGN) shares moved upwards by 24.0% to $0.74 during Monday's after-market session. Kyverna Therapeutics shares increased by 9.19%. Galecto and Ontrak also gained ground. Gritstone Bio and Aclarion were among the losers in the market.
Benzinga · 04/01 20:31
Weekly Report: what happened at BIVI last week (0325-0329)?
Weekly Report · 04/01 09:37
Weekly Report: what happened at BIVI last week (0318-0322)?
Weekly Report · 03/25 09:38
The Law Offices of Frank R. Cruz Reminds Investors of Looming Deadline in the Class Action Lawsuit Against BioVie Inc. (BIVI)
The Law Offices of Frank R. Cruz reminds investors of the upcoming March 19, 2024 deadline to file a lead plaintiff motion in the class action lawsuit. Investors who acquired BioVie Inc. Securities between August 5, 2021 and November 29, 2023 may be eligible to participate.
Barchart · 03/18 11:00
Weekly Report: what happened at BIVI last week (0311-0315)?
Weekly Report · 03/18 09:37
Press Release: BioVie Announces Pipeline Update and Near-Term Clinical Priorities
BioVie Announces Pipeline Update and Near-term Clinical Priorities. Recently completed financing provides sufficient funds for near-term Parkinson's Disease priority. Plans for Phase 2b trial of NE3107 as first-line monotherapy for Parkinson's disease being finalized with targeted launch late-summer 2024. Once-daily NE3 107 formulation expected to be available early 2025 and will be used for Phase 3 trial in Alzheimer's Disease. Company terminated its Phase 3 trials for BIV201 in ascites/liver disease.
Dow Jones · 03/11 12:00
Press Release: BioVie Announces Pipeline Update -2-
A study of the effects of NE3107 on motor activity in a monkey model of Parkinson's Disease. The study was presented at the Alzheimer's and Parkinson's Diseases 2024 conference in Lisbon, Portugal. The researchers found that the monkeys were more responsive to the treatment than other animals.
Dow Jones · 03/11 12:00
Weekly Report: what happened at BIVI last week (0304-0308)?
Weekly Report · 03/11 09:37
BioVie Strengthens Capital with $21M Public Offering
TipRanks · 03/06 22:23
Crude Oil Down Over 1%; Quoin Pharmaceuticals Shares Spike Higher
U.S. Stocks traded lower toward the end of trading on Monday. The Dow traded down 0.20% to 39,007.30 while the NASDAQ fell 0.18%. Super Micro Computer, Inc. Will join the S&P 500 Index on March 18. Utilities shares rose by 0.9% on Monday while communication services shares fell by 1.6%. European shares closed mostly lower while Asian markets closed higher.
Benzinga · 03/04 19:34
Why Bitdeer Technologies Shares Are Trading Higher By 10%? Here Are Other Stocks Moving In Monday's Mid-Day Session
Bitdeer Technologies Group shares jumped 10.2% to $7.45 on Monday. The company announced successful testing of its SEAL01 Bitcoin mining chip. BitFuFu Inc. Shares jumped 107% in the mid-day session. Macy's, Inc. And MGE also rose amid strength in the price of Bitcoin.
Benzinga · 03/04 18:29
12 Health Care Stocks Moving In Monday's Intraday Session
Ocean Biomedical (NASDAQ:OCEA) shares rose 55.0% to $3.1 during Monday's regular session. The company's market cap stands at $105.6 million. Jaguar Health (Jaguar Health) stock moved upwards by 54.8% during the session. Jin Medical International (Jin Medical International) and Ainos (AIMD) were also in the spotlight.
Benzinga · 03/04 17:34
More
Webull provides a variety of real-time BIVI stock news. You can receive the latest news about Biovie Inc through multiple platforms. This information may help you make smarter investment decisions.
About BIVI
BioVie Inc. is a clinical-stage company engaged in developing drug therapies for the treatment of neurological and neurodegenerative disorders and advanced liver disease. In neurodegenerative disease, the Company’s drug candidate NE3107 inhibits inflammatory activation of extracellular single-regulated kinase (ERK) and nuclear factor kappa-light-chain-enhancer of activated B cells (NFkB) that leads to neuroinflammation and insulin resistance, but not their homeostatic functions. In liver disease, its orphan drug candidate BIV201 (continuous infusion terlipressin) is for the treatment of refractory ascites due to liver cirrhosis. BIV201 is administered as a liquid formulation. The Company is also engaged in developing NE3107, an extracellular single-regulated kinase (ERK) inhibitor that selectively reduces neuroinflammation and insulin resistance. NE3107 is an orally administered small molecule to inhibit inflammation-driven insulin resistance and pathological inflammatory cascades.